MARKET

OMER

OMER

Omeros
NASDAQ
14.38
-0.38
-2.57%
Pre Market: 14.37 -0.01 -0.07% 07:23 05/14 EDT
OPEN
14.77
PREV CLOSE
14.76
HIGH
14.86
LOW
13.78
VOLUME
4.57K
TURNOVER
0
52 WEEK HIGH
17.65
52 WEEK LOW
2.950
MARKET CAP
1.04B
P/E (TTM)
-272.8653
1D
5D
1M
3M
1Y
5Y
1D
Omeros expects YARTEMLEA to drive company-wide positive cash flow within 18 months as early TA-TMA uptake builds
Seeking Alpha · 11h ago
Omeros Q1 net income turns positive after YARTEMLEA launch
Reuters · 18h ago
Omeros Non-GAAP EPS of -$0.24 beats by $0.15, revenue of $9.89M beats by $5.78M
Seeking Alpha · 18h ago
Omeros Q1 Adj. EPS $(0.24) Beats $(0.32) Estimate, Sales $9.893M Miss $10.125M Estimate
Benzinga · 18h ago
Press Release: Omeros Corporation Reports First Quarter 2026 Financial Results
Dow Jones · 18h ago
Press Release: Omeros Corporation Reports First -3-
Dow Jones · 18h ago
*Omeros 1Q Net $56.1M >OMER
Dow Jones · 18h ago
Omeros Corporation Reports First Quarter 2026 Financial Results
Barchart · 23h ago
More
About OMER
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan diseases, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The Company's lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. Its lead phosphodiesterase 7 (PDE7) inhibitor, OMS527, is in clinical development for the treatment of cocaine use disorders. The Company also has preclinical programs, including an oncology platform for the development of novel therapeutics.

Webull offers Omeros Corp stock information, including NASDAQ: OMER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OMER stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OMER stock methods without spending real money on the virtual paper trading platform.